Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive ganciclovir or acyclovir in prolonged mechanically ventilated patients with CMV or HSV replication
2012-003312-30Phase 3Active
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV), herpes simplex (HSV), Chronic Critical Illness (CCI) and 1 more comparing Preemptive ganciclovir for CMV replication with Preemptive acyclovir for HSV replication (2 arms). Primary endpoint: alive days without mechanical ventilation to day 60. Started Jun 2013; status: active.
02
Drugs
gancicloviraciclovir
03
Conditions
cytomegalovirus disease (CMV)herpes simplex (HSV)Chronic Critical Illness (CCI)respiratory failure
Beyond the preview
Go deeper on 2012-003312-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003312-30.